Academic Journal
Advances in the clinical applications of sodium thiosulphate.
| Τίτλος: | Advances in the clinical applications of sodium thiosulphate. |
|---|---|
| Συγγραφείς: | Deng Y; Nephrology Department, Jingmen Central Hospital, Hubei University of Medicine, Shiyan, Hubei Province, P.R. China., Ke J; Nephrology Department, Jingmen Central Hospital, Affiliated to Jingchu University of Technology, Jingmen, Hubei Province, P.R. China., Zang H; Nephrology Department, Jingmen Central Hospital, Affiliated to Jingchu University of Technology, Jingmen, Hubei Province, P.R. China., Liu Y; Nephrology Department, Jingmen Central Hospital, Affiliated to Jingchu University of Technology, Jingmen, Hubei Province, P.R. China., Wang P; Nephrology Department, Jingmen Central Hospital, Hubei University of Medicine, Shiyan, Hubei Province, P.R. China.; Nephrology Department, Jingmen Central Hospital, Affiliated to Jingchu University of Technology, Jingmen, Hubei Province, P.R. China. |
| Πηγή: | Annals of medicine [Ann Med] 2026 Dec; Vol. 58 (1), pp. 2611464. Date of Electronic Publication: 2026 Jan 05. |
| Τύπος έκδοσης: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Informa Healthcare Original Publication: Helsinki : Finnish Medical Society Duodecim, 1989- |
| Ιατρικοί όροι (MeSH): | Thiosulfates*/therapeutic use , Thiosulfates*/pharmacology , Antioxidants*/therapeutic use , Antioxidants*/pharmacology , Antidotes*/therapeutic use , Antidotes*/pharmacology, Neoplasms/drug therapy ; Vascular Calcification/drug therapy ; Pruritus/drug therapy ; Humans ; Animals |
| Περίληψη: | Background: Sodium thiosulphate (STS) is a clinically approved pharmaceutical agent known for its antioxidant and sulphide-releasing properties. Currently, it is commonly employed in the detoxification treatment of various chemical intoxications, including cyanide, arsenic, and lead poisoning. In recent years, research into the clinical applications of STS has advanced rapidly, resulting in numerous significant breakthroughs. However, awareness and adoption of these developments remain limited among clinical practitioners. Discussion: In addition to its research progress in the treatment of cyanide poisoning, STS has also demonstrated protective effects against chemotherapeutic drug-induced ototoxicity and nephrotoxicity, as well as in conditions such as vascular calcification and uraemic pruritus. Furthermore, STS has been shown to exert protective effects on multiple organs, including the heart, brain, and kidneys, by mitigating ischaemia-reperfusion injury. There is also evidence suggesting that STS may offer protection in diseases such as preeclampsia and hypertensive renal injury. However, these studies exhibit considerable variability in terms of STS administration strategies. Conclusions: This paper provides a comprehensive review of current preclinical and clinical studies on STS, with the aim of highlighting its potential therapeutic applications in chemical intoxications, cancer treatment, vascular calcification, uraemic pruritus, and other related pathological conditions. Owing to its multiple biological protective effects and a favourable safety profile, STS is anticipated to receive growing recognition among the medical community, which may pave the way for the exploration of novel clinical indications and contribute meaningfully to public health. |
| References: | Front Pharmacol. 2023 Oct 09;14:1203642. (PMID: 37876731) Cochrane Database Syst Rev. 2023 Apr 14;4(2023):CD008320. (PMID: 37314034) J Clin Pharmacol. 1992 Apr;32(4):368-75. (PMID: 1569239) Pharmacology. 2008;82(3):201-13. (PMID: 18810244) Am Heart J. 2022 Jan;243:167-176. (PMID: 34534493) Kidney Med. 2023 Jul 01;5(9):100696. (PMID: 37637864) Front Cardiovasc Med. 2022 Oct 03;9:965965. (PMID: 36262202) Chem Biol Interact. 2017 Aug 25;274:24-34. (PMID: 28688941) Antioxid Redox Signal. 2012 Jul 1;17(1):11-21. (PMID: 22221071) J Am Coll Clin Wound Spec. 2015 Aug 07;6(1-2):24-8. (PMID: 26442208) Theranostics. 2022 Jun 6;12(10):4753-4766. (PMID: 35832084) Otol Neurotol. 2021 Jun 1;42(5):678-685. (PMID: 33710154) Pharmaceuticals (Basel). 2024 Dec 23;17(12):. (PMID: 39770582) Kidney Blood Press Res. 2021;46(1):41-52. (PMID: 33326967) Neuropharmacology. 2003 Sep;45(3):380-93. (PMID: 12871655) Clin J Am Soc Nephrol. 2006 Nov;1(6):1161-6. (PMID: 17699342) J Otolaryngol Head Neck Surg. 2019 Jan 16;48(1):4. (PMID: 30651130) J Bioenerg Biomembr. 2019 Jun;51(3):189-201. (PMID: 30929125) Shock. 2022 Jan 1;57(1):131-139. (PMID: 34172609) Biomolecules. 2024 Nov 07;14(11):. (PMID: 39595596) Clin Toxicol (Phila). 2019 Apr;57(4):265-270. (PMID: 30306816) Redox Biol. 2024 Apr;70:103022. (PMID: 38215546) Ann Emerg Med. 2019 Sep;74(3):423-429. (PMID: 31080026) Arch Dermatol Res. 2022 Aug;314(6):515-525. (PMID: 34165603) Case Rep Nephrol Dial. 2015 Mar 13;5(1):77-82. (PMID: 25874198) BMJ. 2024 Mar 27;384:e077169. (PMID: 38538012) BMC Nephrol. 2024 Jan 22;25(1):26. (PMID: 38254024) Circulation. 2023 Oct 17;148(16):e149-e184. (PMID: 37721023) Ann Surg Oncol. 2022 Jan;29(1):152-162. (PMID: 34350529) Ir J Med Sci. 2023 Dec;192(6):3109-3115. (PMID: 37171573) Int J Mol Sci. 2025 Jan 04;26(1):. (PMID: 39796237) N Engl J Med. 2018 Jun 21;378(25):2376-2385. (PMID: 29924955) Ann Emerg Med. 2017 Jun;69(6):718-725.e4. (PMID: 28041825) Front Med (Lausanne). 2025 Sep 10;12:1627955. (PMID: 41001391) BMC Nephrol. 2022 Jan 3;23(1):4. (PMID: 34979980) J Med Toxicol. 2021 Jul;17(3):257-264. (PMID: 33821433) J Clin Oncol. 2024 Jun 20;42(18):2219-2232. (PMID: 38648563) Ann Emerg Med. 2001 Jun;37(6):635-41. (PMID: 11385334) J Clin Oncol. 1985 Feb;3(2):237-44. (PMID: 4038510) Clin J Am Soc Nephrol. 2011 Jun;6(6):1447-55. (PMID: 21566113) Int J Mol Sci. 2024 Sep 02;25(17):. (PMID: 39273476) Pediatr Blood Cancer. 2020 Nov;67(11):e28647. (PMID: 32886425) Pediatr Blood Cancer. 2023 May;70(5):e30248. (PMID: 36772889) Cardiovasc J Afr. 2023 Jul 3;34:1-10. (PMID: 37526956) Cardiovasc Drugs Ther. 2017 Dec;31(5-6):511-524. (PMID: 28965151) Pleura Peritoneum. 2022 May 2;7(2):87-93. (PMID: 35812006) Theranostics. 2023 Jul 31;13(13):4356-4375. (PMID: 37649595) Nephrology (Carlton). 2023 Jun;28(6):305-314. (PMID: 36883928) Complement Ther Med. 2019 Aug;45:248-253. (PMID: 31331569) Clin Case Rep. 2018 Jul 01;6(8):1595-1599. (PMID: 30147912) Diagnostics (Basel). 2022 Apr 28;12(5):. (PMID: 35626264) Anal Biochem. 2011 Jun 1;413(1):1-7. (PMID: 21303647) Toxicol Appl Pharmacol. 1995 Oct;134(2):229-34. (PMID: 7570599) Cell Death Differ. 2024 Dec;31(12):1636-1649. (PMID: 39169174) Chem Res Toxicol. 2021 Jun 21;34(6):1530-1541. (PMID: 33914522) Ren Fail. 2025 Dec;47(1):2456690. (PMID: 39865575) Redox Biol. 2025 May;82:103595. (PMID: 40107018) Curr Opin Plant Biol. 2024 Oct;81:102608. (PMID: 39089185) Pediatr Blood Cancer. 2023 Jul 7;:e30550. (PMID: 37416942) Biochimie. 2018 Apr;147:80-88. (PMID: 29366934) Medicina (Kaunas). 2023 Jul 14;59(7):. (PMID: 37512116) Int J Mol Sci. 2023 Nov 20;24(22):. (PMID: 38003734) J Clin Aesthet Dermatol. 2021 Oct;14(10):48-51. (PMID: 34976291) EBioMedicine. 2022 Apr;78:103954. (PMID: 35334307) JAMA Oncol. 2025 Jun 1;11(6):636-643. (PMID: 40272825) Nephron. 2018;139(3):219-227. (PMID: 29587288) J Inorg Biochem. 2016 Sep;162:96-101. (PMID: 27324827) Biomolecules. 2020 Feb 14;10(2):. (PMID: 32075042) Ren Fail. 2025 Dec;47(1):2432538. (PMID: 39763079) Ren Fail. 2025 Dec;47(1):2453627. (PMID: 39842817) Arch Dermatol Res. 2025 Jan 18;317(1):288. (PMID: 39825932) Calcif Tissue Int. 2021 Jun;108(6):798-807. (PMID: 33439323) Ren Fail. 2020 Nov;42(1):987-993. (PMID: 32967516) Pediatr Nephrol. 2024 Jan;39(1):25-35. (PMID: 37171581) Mayo Clin Proc. 2018 Sep;93(9):1164-1166. (PMID: 30193670) J Cancer Surviv. 2023 Feb;17(1):4-16. (PMID: 36637630) Kidney Int. 2020 Aug;98(2):366-377. (PMID: 32605800) Drugs. 2019 Sep;79(14):1567-1582. (PMID: 31429065) J Org Chem. 2019 Sep 6;84(17):11294-11300. (PMID: 31393123) PLoS One. 2021 Jan 20;16(1):e0245370. (PMID: 33471852) ACS Nano. 2023 Dec 26;17(24):24773-24789. (PMID: 38055864) Nat Clin Pract Nephrol. 2009 Mar;5(3):157-70. (PMID: 19190625) Mol Med Rep. 2019 May;19(5):3622-3632. (PMID: 30896801) Clin Toxicol (Phila). 2017 Sep;55(8):929-933. (PMID: 28494173) Biomolecules. 2022 Apr 04;12(4):. (PMID: 35454132) ASAIO J. 2022 Mar 1;68(3):402-406. (PMID: 34294642) Clin Toxicol (Phila). 2020 Apr;58(4):290-293. (PMID: 31322009) Indian J Pharmacol. 2017 Jul-Aug;49(4):317-321. (PMID: 29326493) Am J Nurs. 2023 Jan 1;123(1):23. (PMID: 36546383) J Nephrol. 2021 Feb;34(1):23-25. (PMID: 32418117) Ther Apher Dial. 2023 Dec;27(6):1079-1087. (PMID: 37424269) Hemodial Int. 2025 Apr;29(2):238-241. (PMID: 39837779) JAMA Netw Open. 2021 Aug 2;4(8):e2118895. (PMID: 34338793) Redox Biol. 2021 Jul;43:101961. (PMID: 33848877) Nephrol Dial Transplant. 2020 Jan 1;35(1):162-169. (PMID: 31764989) Molecules. 2016 Dec 21;21(12):. (PMID: 28009842) Naunyn Schmiedebergs Arch Pharmacol. 2023 Oct;396(10):2587-2598. (PMID: 37058187) Ann Surg Oncol. 2023 Dec;30(13):8115-8137. (PMID: 37561343) Adv Chronic Kidney Dis. 2019 Nov;26(6):484-490. (PMID: 31831126) Am J Physiol Regul Integr Comp Physiol. 2011 Aug;301(2):R297-312. (PMID: 21543637) Kidney Res Clin Pract. 2023 Jan;42(1):39-52. (PMID: 35545226) J Control Release. 2021 Sep 10;337:59-70. (PMID: 34273418) World J Urol. 2023 Nov;41(11):2959-2966. (PMID: 37782324) Kidney Int Rep. 2025 Jun 24;10(9):2991-3005. (PMID: 40980656) Nephrol Dial Transplant. 2023 Feb 28;38(3):733-745. (PMID: 35521751) PLoS One. 2015 Apr 30;10(4):e0124881. (PMID: 25928142) Eur J Surg Oncol. 2024 Feb;50(2):107955. (PMID: 38219699) Ren Fail. 2023;45(2):2254569. (PMID: 37755153) Lancet Oncol. 2017 Jan;18(1):63-74. (PMID: 27914822) Cureus. 2023 Jul 27;15(7):e42587. (PMID: 37641756) Lancet Oncol. 2022 May;23(5):570-572. (PMID: 35489339) J Am Acad Dermatol. 2024 Jan;90(1):45-51. (PMID: 37586460) Kidney Int. 2015 Apr;87(4):685-91. (PMID: 24402092) Lancet Child Adolesc Health. 2020 Feb;4(2):141-150. (PMID: 31866182) Int J Hyperthermia. 2020;37(1):897-902. (PMID: 32689832) Acta Biomed. 2023 Oct 17;94(5):e2023241. (PMID: 37850777) Kidney Int. 2022 May;101(5):987-1002. (PMID: 35227690) Food Chem. 2024 Oct 30;456:139872. (PMID: 38865818) Nat Chem Biol. 2015 Jul;11(7):457-64. (PMID: 26083070) PLoS One. 2021 May 13;16(5):e0251408. (PMID: 33984042) Clin Cancer Res. 2000 Jan;6(1):309-15. (PMID: 10656463) Curr Opin Rheumatol. 2024 Nov 1;36(6):453-458. (PMID: 39120537) Exp Ther Med. 2019 Jan;17(1):863-868. (PMID: 30651873) Ren Fail. 2025 Dec;47(1):2489712. (PMID: 40260510) JAMA. 2024 Jun 25;331(24):2114-2124. (PMID: 38809527) J Card Surg. 2019 Oct;34(10):1137-1139. (PMID: 31389631) Pediatr Blood Cancer. 2025 May;72(5):e31631. (PMID: 40032793) Ren Fail. 2022 Dec;44(1):914-922. (PMID: 35634730) Best Pract Res Clin Rheumatol. 2022 Jun;36(2):101768. (PMID: 35803868) J Am Soc Nephrol. 2022 May;33(5):1011-1032. (PMID: 35232774) Toxins (Basel). 2021 Oct 30;13(11):. (PMID: 34822553) Adv Sci (Weinh). 2024 Jul;11(28):e2400527. (PMID: 38689508) Br J Dermatol. 2020 Aug;183(2):367-372. (PMID: 31646622) Drug Saf. 2001 Jan;24(1):19-38. (PMID: 11219485) J Educ Teach Emerg Med. 2022 Jul 15;7(3):S1-S25. (PMID: 37465777) Am J Kidney Dis. 2023 Feb;81(2):232-239. (PMID: 35970430) Int J Biol Sci. 2023 Jan 1;19(1):294-310. (PMID: 36594097) Adv Healthc Mater. 2025 Jul;14(18):e2500856. (PMID: 40417956) Semin Arthritis Rheum. 2023 Dec;63:152306. (PMID: 37976811) Paediatr Drugs. 2023 Mar;25(2):239-244. (PMID: 36517667) Int J Mol Sci. 2021 Jun 16;22(12):. (PMID: 34208631) |
| Contributed Indexing: | Keywords: Sodium thiosulphate; cisplatin; cyanide; ischaemia-reperfusion; uraemic pruritus; vascular calcification |
| Substance Nomenclature: | HX1032V43M (sodium thiosulfate) 0 (Thiosulfates) 0 (Antioxidants) 0 (Antidotes) |
| Entry Date(s): | Date Created: 20260106 Date Completed: 20260106 Latest Revision: 20260903 |
| Update Code: | 20260903 |
| PubMed Central ID: | PMC12778002 |
| DOI: | 10.1080/07853890.2025.2611464 |
| PMID: | 41490376 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1365-2060 |
|---|---|
| DOI: | 10.1080/07853890.2025.2611464 |